Provided by Tiger Trade Technology Pte. Ltd.

TRAWS PHARMA

0.5600
+0.03005.66%
Post-market: 0.5490-0.0110-1.96%19:54 EDT
Volume:76.50K
Turnover:41.56K
Market Cap:8.61M
PE:-0.26
High:0.5650
Open:0.5551
Low:0.5300
Close:0.5300
52wk High:3.27
52wk Low:0.4301
Shares:15.37M
Float Shares:12.18M
Volume Ratio:0.56
T/O Rate:0.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1348
EPS(LYR):0.8343
ROE:-433.36%
ROA:-99.40%
PB:5.09
PE(LYR):0.67

Loading ...

Traws Pharma Price Target Maintained with a $1.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 18

Analysts Offer Insights on Healthcare Companies: Invivyd (IVVD), Traws Pharma (TRAW) and DocGo (DCGO)

TIPRANKS
·
Aug 18

Traws Pharma Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 15

Traws Pharma Q2 EPS $(0.16) Beats $(0.34) Estimate

Benzinga Earnings
·
Aug 15

Traws Pharma Q2 Revenue Falls to Zero on Licensing Termination; Net Loss Widens

Reuters
·
Aug 15

Traws Pharma - no Revenue Recognized for Q2

THOMSON REUTERS
·
Aug 15

Traws Pharma Inc Q2 Net Income USD -3 Million

THOMSON REUTERS
·
Aug 15

Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights

THOMSON REUTERS
·
Aug 15

Traws Pharma Inc Expected to Post a Loss of 34 Cents a Share - Earnings Preview

Reuters
·
Aug 10

TRAW Moves TRX-100 Through Early Human Testing: What Investors Should Watch

TIPRANKS
·
Aug 04

Traws Pharma Risks NASDAQ Delisting After Shares Trade Below $1 for 30 Days

Reuters
·
Aug 01

Traws Pharma Launches At-the-market Offering of up to $5.58 Million in Shares

Reuters
·
Jul 11

Traws Pharma Holds Annual Shareholder Meeting in Virtual Format

Reuters
·
Jul 10

Traws Pharma files $139.19M mixed securities shelf

TIPRANKS
·
Jul 02

Traws Pharma Inc Files for Mixed Shelf Offering of up to $139.2 Mln - Filing

THOMSON REUTERS
·
Jul 02

Traws Pharma Says Updated Toxicology Data Being Developed on Influenza Prophylaxis Program

MT Newswires Live
·
Jun 22

BRIEF-Traws Pharma Provides Updated Guidance On Influenza Prophylaxis Program

Reuters
·
Jun 22

Traws Pharma targets 3Q 2026 MHRA resubmission to advance TXM Phase 2a influenza challenge study

Reuters
·
Jun 22

Traws Pharma - Preparing Updated Toxicology Data for Mhra Tivoxavir Marboxil Phase 2a Study

THOMSON REUTERS
·
Jun 22

Traws Pharma - Company Expects Mhra Response Within 30 Days of Resubmission

THOMSON REUTERS
·
Jun 22